BOSTON, March 5, 2026 — Leads & Copy — CervoMed Inc. (NASDAQ: CRVO) will participate in investor conferences this month, the company announced today.
Management from the clinical-stage biotechnology company, which develops treatments for age-related brain disorders, will attend the Leerink Global Healthcare Conference on Wednesday, March 11, 2026. They will also participate in the 38th Annual ROTH Conference, where they will host a fireside chat and investor meetings.
The fireside chat presentation is scheduled for Monday, March 23, 2026, from 12:00 – 12:30 PM PT. A webcast of the chat will be available in the Investor section of CervoMed’s website.
CervoMed is focused on developing treatments for age-related brain disorders. Their lead drug candidate, neflamapimod, is an oral small molecule designed to inhibit a key enzyme involved in neuroinflammation and neurodegeneration. The company recently completed Phase 2b RewinD-LB trial that evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology. CervoMed plans to begin a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, pending available funding.
Source: CervoMed
